CanSino Biologics

Company snapshot

CanSino Biologics ([simplified Chinese](en.wikipedia.org/wiki/Simplified_Chinese): 康希诺生物; [traditional Chinese](en.wikipedia.org/wiki/Traditional_Chines): 康希諾生物; [pinyin](en.wikipedia.org/wiki/Pinyin): Kāngxīnuò Shēngwù), often abbreviated as CanSinoBIO, is a Chinese [vaccine](en.wikipedia.org/wiki/Vaccine) company. | Trade name | CanSinoBIO | | --- | --- | | Native name | 康希诺生物 | | Traded as | SE

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for CanSino Biologics. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for CanSino Biologics.

1. Jun 8, 2026 Clinical update

   CTP-VLP-002 — Phase 2

2. Jun 8, 2026 Clinical update

   Tuberculosis (TB) vaccine (Ad5-105K) — Phase 1

3. Jun 8, 2026 Clinical update

   batch 1 of Group ACYW135 Meningococcal Conjugate Vaccine (CRM197) (MCV4) — Phase 3

View all clinical trial activity →

• What is CanSino Biologics?

  CanSino Biologics is a pharma organization headquartered in CN. Primary therapeutic focus areas include Tuberculosis, Meningococcal Meningitis, Poliomyelitis. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA

• Is CanSino Biologics publicly traded?

  CanSino Biologics appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does CanSino Biologics develop or market?

  We link 9 drug profile(s) where CanSino Biologics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/cansino-biologics#company-drugs.

• What are the latest developments for CanSino Biologics?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does CanSino Biologics focus on?

  CanSino Biologics focuses on Tuberculosis, Meningococcal Meningitis, Poliomyelitis based on our analysis of their pipeline programs and drug development activities.